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Background. From 2015–2016 through 2017–2018, injectable, trivalent inactivated influenza vaccines (IIV3) and a nasal spray, 
tetravalent live-attenuated influenza vaccine (LAIV4) were used in parallel in Finland. To understand how well vaccination with 
each vaccine type protected children against influenza under real-life conditions, vaccine effectiveness in 2-year-olds was estimated 
for all 3 seasons.
Methods. Each season, a nationwide register-based cohort study was conducted. The study population comprised 60 088, 
60 860, and 60 345 children in 2015–2016, 2016–2017, and 2017–2018, respectively. Laboratory-confirmed influenza was the study 
outcome. Seasonal influenza vaccination with either LAIV4 or IIV3 was the time-dependent exposure of interest. Vaccine effective-
ness was defined as 1 minus the hazard ratio comparing vaccinated with unvaccinated children.
Results. From 2015–2016 through 2017–2018, the effectiveness of LAIV4 against influenza of any virus type was estimated at 
54.2% (95% confidence interval, 32.2–69.0%), 20.3% (−12.7%, 43.6%), and 30.5% (10.9–45.9%); the corresponding effectiveness of 
IIV3 was 77.2% (48.9–89.8%), 24.5% (−29.8%, 56.1%), and −20.1% (−61.5%, 10.7%). Neither influenza vaccine clearly excelled in 
protecting children. The LAIV4 effectiveness against type B was greater than against type A and greater than the IIV3 effectiveness 
against type B.
Conclusions. To understand how influenza vaccines could be improved, vaccine effectiveness must be analyzed by vaccine and 
virus type. Effectiveness estimates also expressing overall protection levels are needed to guide individual and programmatic deci-
sion-making processes. Supported by this analysis, the vaccination program in Finland now recommends LAIV4 and injectable, 
tetravalent inactivated influenza vaccines replacing IIV3.
Keywords.  vaccine effectiveness; influenza; children; cohort study; Finland.
For more than a decade, annual vaccination against influ-
enza has been recommended to children aged 6–35 months in 
Finland [1]. Injectable, inactivated influenza vaccine has been 
given free of charge to all eligible children since 2007. To en-
hance vaccine uptake, the tetravalent live-attenuated influenza 
vaccine (LAIV4) administered as nasal spray was introduced in 
2015 [2]. Since then, all 2-year-old children have been eligible 
for vaccination with LAIV4 or inactivated influenza vaccine 
without a recommended preference. As expected, vaccination 
coverage has increased steadily following LAIV4 introduction. 
While in 2014–2015 only 11% of children aged 6–35  months 
were vaccinated, 17%, 22%, and 24% were vaccinated in the 
3 subsequent seasons (2015–2016, 2016–2017, and 2017– 
2018) [3].
Through 2017–2018, the 2 types of influenza vaccine pro-
vided by the vaccination program differed in valency as tri-
valent inactivated influenza vaccines (IIV3) always contained 
only 1 of the 2 influenza B components of LAIV4. Moreover, 
the vaccination program recommended 2 shots (at least 4 weeks 
apart) instead of only 1 if a child was to receive IIV3 and had not 
received either LAIV4 or 2 shots of IIV3 in previous seasons.
To understand how well vaccination protects against influ-
enza under real-life conditions, vaccine effectiveness (VE) is 
estimated each season in Finland [4] as well as in many other 
countries [5]. However, VE appears to vary widely across sea-
sons and countries. Known factors contributing to any true 
diversity in VE include differences in the circulating strains 
or in the age and vaccination history of the populations. It is 
thus apparent that genetic characterization of influenza viruses, 
power to stratify by age, and individual-level information on 
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these demands can be met through studies utilizing population-
based data from routine health registers [4].
In this article, we employ Finnish register data to estimate in-
fluenza VE in 2-year-old children by vaccine and influenza type. 
We focus on the 3 influenza seasons 2015–2016, 2016–2017, 
and 2017–2018, when LAIV4 was used in parallel with IIV3.
METHODS
We conducted 3 register-based cohort studies in Finland [4]. The 
study periods of interest were 3 influenza seasons—2015–2016, 
2016–2017, and 2017–2018—each defined as starting at the first 
day of week 40 and ending at the last day of week 20.
Each season, the study population consisted of all 2-year-olds 
registered in the Population Information System [4]. We thus 
studied 3 partly overlapping cohorts of children alive at season 
onset and born November 2012–December 2013, November 
2013–December 2014, and November 2014–December 
2015, respectively. The exclusion criteria were history of resi-
dence abroad and residence outside the National Vaccination 
Register’s (NVR’s) [6] catchment area at season onset or in any 
previous season.
The outcome of interest was laboratory-confirmed influ-
enza infection during the respective season, recorded in the 
National Infectious Diseases Register allowing distinction be-
tween cases of influenza A and influenza B [4]. The clinical pre-
sentation and severity of infection were unknown. As a proxy, 
however, we extracted hospitalization dates from the Care 
Register of Health Care [4] to count how many cases were hos-
pitalized within 7 days since the influenza-positive specimen 
was sampled.
The exposure of interest was seasonal influenza vaccination 
with either LAIV4 or IIV3, recorded in the NVR [4]. Also, vac-
cinations given shortly before the respective season onset (ie, 
vaccinations from August through week 39) were included. We 
distinguished between 3 time-dependent exposure states: un-
vaccinated, partially vaccinated, and fully vaccinated. Until the 
first receipt of any influenza vaccine a child was considered un-
vaccinated and thereafter partially vaccinated until being fully 
vaccinated. A child was considered fully vaccinated with LAIV4 
since day 15 after the first receipt of LAIV4. A child was con-
sidered fully vaccinated with IIV3 since day 15 after the second 
receipt of IIV3 or since day 15 after the first receipt of IIV3 if 
the child had already been vaccinated in previous seasons with 
LAIV4 or 2 shots of IIV3.
For each season, we conducted 2 separate analyses using vac-
cination with either LAIV4 or IIV3 as the exposure. Each child 
was considered to be at risk of the outcome of interest (influ-
enza A, influenza B, or any influenza) from season onset until 
the first of the following events: outcome of interest, vaccination 
with an influenza vaccine other than the exposure, loss to fol-
low-up (due to death or emigration outside the NVR’s catch-
ment area), or end of the study period [4].
The effect measure of interest was VE defined as 1 minus 
the hazard ratio comparing fully vaccinated children with un-
vaccinated children [4]. The hazard ratio was estimated using 
Cox regression with time since season onset as the underlying 
time scale. The validity of the proportional hazards assump-
tion was checked visually by plotting nonparametric estimates 
of the hazards in the vaccinated and the unvaccinated children 
over time. In a sensitivity analysis, the estimation of VE was 
restricted to children not vaccinated against influenza in any 
previous season. Demographic and health-related background 
information was collected as listed in Supplementary Tables 1 
and 2 to describe potential differences in influenza incidence 
and vaccine uptake.
Individual-level data from different registers were linked de-
terministically using the unique personal identity code assigned 
to all permanent Finnish residents [4]. All analyses were con-
ducted in R 3.5.3 (R Foundation for Statistical Computing) [7].
RESULTS
Size of Study Population
In 2015–2016, the study population comprised 60 088 children 
of whom 1 child was excluded from the LAIV4 analysis due to 
vaccination with IIV3 before week 40, 2015 (Figure 1). In the 
subsequent 2 seasons, the study populations were 60 860 chil-
dren (2016–2017) and 60 345 children (2017–2018). Seven chil-
dren were excluded from the LAIV4 analysis in 2016–2017 and 
8 were excluded in 2017–2018 (Figure 1).
Number of Influenza Cases
There were 309 influenza A and 79 influenza B cases in 2015–
2016, 273 influenza A  and 9 influenza B cases in 2016–2017, 
and 268 influenza A and 237 influenza B cases in 2017–2018. 
Repeated infections and coinfections were rare, occurring 
6 times in 2015–2016 and 3 and 11 times in the subsequent 
2 seasons. Only a few children were hospitalized: 61 influenza 
A and 12 influenza B cases in 2015–2016, 38 influenza A cases 
in 2016–2017, and 19 influenza A and 32 influenza B cases in 
2017–2018.
Distribution of Vaccine Brands
Throughout the 3 seasons, Fluenz Tetra (AstraZeneca)  was 
the only administered LAIV4 brand, while altogether, 4 IIV3 
brands were used. The 2015–2016 IIV3 brands were Vaxigrip 
(Sanofi Pasteur) (99.8% of 6329 IIV3 doses), Influvac (Abbott) 
(0.2%), and Fluarix (GlaxoSmithKline) (0.0%; 2 children 
were vaccinated with Fluarix although this brand was recom-
mended not to be used in this age group). The 2016–2017 IIV3 
brands were Influvac (Abbott) (99.8% of 6938 IIV3 doses) and 
Vaxigrip (Sanofi Pasteur) (0.2%). In 2017–2018, children were 
vaccinated with Influvac (Abbott) (88.4% of 6494 IIV3 doses) 
and Agrippal (Seqirus) (11.6%). In each season, there was a 
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24 (2015–2016), 59 (2016–2017), and 87 (2017–2018). The 
majority of the children were vaccinated first with IIV3.
Timing of Influenza Epidemic and Vaccine Uptake
Supplementary Figures 1 and 2 show the timing of the influ-
enza epidemic and the vaccine uptake in the study population. 
When the 2015–2016 influenza incidence reached its peak in 
week 4, 2016, most LAIV4 recipients had been fully vaccinated, 
but the number of children fully vaccinated with IIV3 was still 
increasing. In 2016–2017, the influenza incidence peaked al-
ready in week 52, 2016, when the vaccination campaign had not 
yet completed. Consequently, the percentage of children fully 
vaccinated with either LAIV4 or IIV3 was still increasing there-
after. When the 2017–2018 influenza incidence reached its peak 
in week 11, 2018, almost all vaccinations (LAIV4 and IIV3) had 
been administered. However, the epidemic had started early co-
inciding with the last weeks of the vaccination campaign.
Vaccination Coverage
In 2015–2016, 14% of the children were fully vaccinated with 
LAIV4 (Table 1, Supplementary Table 3) and 7% were fully vac-
cinated with IIV3 (Table 2, Supplementary Table 4) by the end of 
follow-up. These percentages increased to 20% (LAIV4) (Table 1) 
and 8% (IIV3) (Table 2) in 2016–2017 and 22% (LAIV4) (Table 1) 
and 9% (IIV3) (Table 2) in 2017–2018. Simultaneously, the pro-
portion of children at season onset who were not vaccinated 
against influenza in any previous season decreased from 77.1% 
(2015–2016) to 70.5% (2016–2017) to 61.6% (2017–2018). In 
2015–2016, no child had been previously vaccinated with LAIV4.
Vaccine Effectiveness
The VE of LAIV4 against influenza A and influenza B was esti-
mated at 45.8% (95% confidence interval [CI], 32.2–69.0%) and 
83.4% (32.3–95.9%) in 2015–2016 (Table 1, Figure 2). The cor-
responding figures for IIV3 were 90.3% (95% CI, 60.9–97.6%) 
and 34.6% (−79.5% to 76.1%) (Table  2, Figure  2). Restricting 
the analysis to children not previously vaccinated lowered the 
point estimates to 25.8%, 79.9%, 65.4%, and 22.4% and broad-
ened the CIs, all of which contained the null hypothesis value of 
0% (Supplementary Tables 5 and 6).
The VE of LAIV4 against influenza A and influenza B was 
estimated at 21.1% (95% CI, −12.1% to 44.4%) and 31.1% 
(−466.7% to 91.6%) in 2016–2017 (Table  1, Figure  2). Being 
fully vaccinated with IIV3 reduced the influenza A  incidence 
rate by 23.1% (95% CI, −32.3% to 55.3%) (Table 2, Figure 2). 
There were no influenza B cases among those who were fully 
vaccinated with IIV3 (Table 2).
The VE of LAIV4 against influenza A and influenza B was es-
timated at −21.8% (95% CI, −62.4% to 8.7%) and 75.4% (57.7–
85.7%) in 2017–2018 (Table  1, Figure  2). The corresponding 
figures for IIV3 were −42.0% (95% CI, −110.6% to 4.2%) and 
−0.2% (−55.9% to 35.6%) (Table  2, Figure  2). Restricting the 
analysis to children not previously vaccinated lowered the point 
estimates for LAIV4 against influenza B to 71.5% (95% CI, 
23.1–89.4%) (Supplementary Table 5).
Baseline Differences in Influenza Incidence and Vaccine Uptake
The point estimates of the incidence of laboratory-confirmed 
influenza infection in unvaccinated children varied moderately 
Figure 1. Enrollment of the study population (2-year-old children) into the cohorts: influenza seasons 2015–2016 through 2017–2018, Finland. Abbreviations: IIV3, trivalent 
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across the categories of the 20 considered baseline character-
istics (Supplementary Table 7). However, the only 2 charac-
teristics consistently associated with the incidence over the 
3 seasons were “presence of acute disease between weeks 21 
and 39” and “presence of underlying chronic conditions be-
fore season onset.” The incidence among unvaccinated chil-
dren with an acute disease or underlying chronic condition was 
66.3% higher than the incidence among those without. The by 
far highest incidence of 29 cases per 10 000 person-weeks was 
observed in 2015–2016 in the 36 children born extremely pre-
term (before the gestational age of 28 weeks).
In each season under study, children born in November or 
December were more likely to receive IIV3 as their first influ-
enza vaccine (Supplementary Tables 8–10). However, the es-
timated influenza incidence did not differ much by month of 
birth, except for children born in November or December, who 
had a slightly lower risk of laboratory-confirmed influenza in-
fection in 2016–2017 (Supplementary Table 7).
In addition, residence and the number of well-baby clinic visits 
may have affected the vaccine uptake and influenza incidence. 
Children living in urban municipalities were more likely to be 
vaccinated than children living in rural municipalities, where the 
Table 1. Vaccine Effectiveness of LAIV4 Against Laboratory-Confirmed Influenza Infection in 2-Year-Old Children: Influenza Seasons 2015–2016 Through 
2017–2018, Register-based Cohort Studies, Finland
Season and Influenza 
Virus Type
Unvaccinated Fully Vaccinated
HR (95% CI) VE (95% CI), %Cases,a n
Population,a,b 
n (%) Incidencec Cases,a n
Population,a,b 
n (%) Incidencec
2015–2016 (N = 60 087)         
 Any 339 51 639 (85.9) 2.003 27 8442 (14.0) 1.354 0.458 (.310–.678) 54.2 (32.2–69.0)
 A 277 51 639 (85.9) 1.636 26 8445 (14.1) 1.303 0.542 (.363–.811) 45.8 (18.9–63.7)
 B 67 51 638 (85.9) 0.395 2 8445 (14.1) 0.100 0.166 (.041–.677) 83.4 (32.3–95.9)
2016–2017 (N = 60 853)         
 Any 221 48 914 (80.4) 1.431 38 11 937 (19.6) 1.361 0.797 (.564–1.127) 20.3 (−12.7 to 43.6)
 A 217 48 914 (80.4) 1.405 37 11 938 (19.6) 1.325 0.789 (.556–1.121) 21.1 (−12.1 to 44.4)
 B 7 48 911 (80.4) 0.045 1 11 941 (19.6) 0.036 0.689 (.084–5.667) 31.1 (−466.7 to 91.6)
2017–2018 (N = 60 337)         
 Any 354 47 270 (78.3) 2.369 75 13 056 (21.6) 2.445 0.695 (.541–.891) 30.5 (10.9–45.9)
 A 171 47 269 (78.3) 1.143 64 13 062 (21.6) 2.085 1.218 (.913–1.624) −21.8 (−62.4 to 8.7)
 B 189 47 270 (78.3) 1.263 14 13 058 (21.6) 0.455 0.246 (.143–.423) 75.4 (57.7–85.7)
Abbreviations: CI, confidence interval; HR, hazard ratio; LAIV4, tetravalent live-attenuated influenza vaccine; VE, vaccine effectiveness.
aVaccination status at the end of follow-up. See Supplementary Table 3 for cases and population partially vaccinated at the end of follow-up.
bProportion of cohort size N.
cPer 10 000 person-weeks.
Table 2. Vaccine Effectiveness of IIV3 Against Laboratory-Confirmed Influenza in 2-Year-Old Children: Influenza Seasons 2015–2016 Through 2017–2018, 
Register-based Cohort Studies, Finland
Season and Influenza 
Virus Type
Unvaccinated Fully Vaccinated
HR (95% CI) VE (95% CI), %Cases,a n
Population,a,b 
n (%) Incidencec Cases,a n
Population,a,b 
n (%) Incidencec
2015–2016 (N = 60 088)         
 Any 339 54 872 (91.3) 2.003 6 4418 (7.4) 0.648 0.228 (.102–.511) 77.2 (48.9–89.8)
 A 277 54 872 (91.3) 1.636 2 4418 (7.4) 0.216 0.097 (.024–.391) 90.3 (60.9–97.6)
 B 67 54 869 (91.3) 0.395 4 4419 (7.4) 0.432 0.654 (.239–1.795) 34.6 (−79.5 to 76.1)
2016–2017 (N = 60 860)         
 Any 221 54 967 (90.3) 1.431 14 5071 (8.3) 1.220 0.755 (.439–1.298) 24.5 (−29.8 to 56.1)
 A 217 54 967 (90.3) 1.405 14 5071 (8.3) 1.220 0.769 (.447–1.323) 23.1 (−32.3 to 55.3)
 B 7 54 966 (90.3) 0.045 0 5075 (8.3) 0.000 Not estimated Not estimated
2017–2018 (N = 60 345)         
 Any 354 54 435 (90.2) 2.369 50 5158 (8.5) 4.140 1.201 (.893–1.615) −20.1 (−61.5 to 10.7)
 A 171 54 434 (90.2) 1.143 29 5161 (8.6) 2.395 1.420 (.958–2.106) −42.0 (−110.6 to 4.2)
 B 189 54 435 (90.2) 1.263 22 5158 (8.5) 1.817 1.002 (.644–1.559) −0.2 (−55.9 to 35.6)
Abbreviations: CI, confidence interval; HR, hazard ratio; IIV3, trivalent inactivated influenza vaccine; VE, vaccine effectiveness.
aVaccination status at the end of follow-up. See Supplementary Table 4 for cases and population partially vaccinated at the end of follow-up.
bProportion of cohort size N.
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incidence among the unvaccinated was lower than in urban mu-
nicipalities. Likewise, children who had visited well-baby clinics 
more than 17 times before the age of 2 years  were more likely to 
be vaccinated than children who had visited well-baby clinics less 
than 12 times (Supplementary Tables 8–10). The influenza inci-
dence in unvaccinated children who had visited well-baby clinics 
more than 17 times was higher than in unvaccinated children who 
had visited well-baby clinics less often (Supplementary Table 7).
DISCUSSION
In Finland, the influenza vaccine uptake among 2-year-olds has 
been steadily increasing. The VE, however, dropped from being 
initially high in 2015–2016 to rather low levels in 2016–2017 
and 2017–2018. According to the presented register-based co-
hort studies, vaccination with LAIV4 or IIV3 reduced the influ-
enza incidence rate by more than half in 2015–2016 but by less 
than one-third in the 2 subsequent seasons. The small number 
of hospitalized cases indicates that the majority of infections in 
children were detected and treated in primary care.
It is known from sentinel surveillance that the 2015–2016 in-
fluenza epidemic was predominated by A(H1N1)pdm09 and B/
Victoria viruses, although the latter type circulated mainly towards 
the end of the season and to a much lesser extent [8]. According 
to our analysis, IIV3 provided better protection against influenza 
A than LAIV4. Since both contained A(H1N1)pdm09 virus an-
tigen, the observed difference may be due to reduced replicative 
fitness of the A(H1N1)pdm09 component in LAIV4 [9]. Against 
influenza B, however, LAIV4 provided stronger protection than 
IIV3, which did not contain B/Victoria virus antigen in 2015–
2016 and was thus mismatched with the circulating influenza B 
viruses. These findings are in line with results obtained in other 
studies on VE of LAIV4 and/or IIV3 in children from Canada 
[10], Israel [11], the United Kingdom [12, 13], and the United 
States [14]. Nevertheless, there have also been dissenting studies 
indicating lack of protection after vaccination with LAIV4, based 
on which the recommendation of using live-attenuated influenza 
vaccines was withdrawn in the United States [15].
The 2016–2017 epidemic in Finland was predominated 
by influenza A(H3N2) viruses [16], against which neither 
LAIV4 nor IIV3 was found to be efficacious. By contrast, 
a study conducted in the United Kingdom estimated VE of 
LAIV4 against influenza A(H3N2) at 57% [17], although 
the CI is wide and includes our point estimate. Focusing on 
IIV3, 3 studies in outpatient care did not show strong ben-
eficial effects [18–20], while a fourth, hospital-based study 
did [11]. In general, VE against A(H3N2) strains has been 
consistently lower when compared with VE against other 
strains. Suggested reasons include the rapid evolution of 
wild A(H3N2) viruses, egg-based manufacturing of vac-
cines increasing the chance of antigenic mismatch due to egg 
adaption, and the complexity of human immune responses 
such as the imprinting effect of the first encountered infec-
tion [21, 22]. Due to the small number of influenza B cases 
among Finnish 2-year-olds it was not possible to estimate VE 
against influenza B in 2016–2017.
In 2017–2018, influenza A(H3N2) and B/Yamagata viruses 
co-circulated [23]. Neither LAIV4 nor IIV3 protected Finnish 
children against influenza A.  Nevertheless, vaccination with 
LAIV4 was still beneficial due to its high effectiveness against 
influenza B. By contrast, the effectiveness of IIV3 against influ-
enza B was estimated at 0%. Again, the trivalent vaccine compo-
sition mismatched with the circulating influenza B viruses. Our 
results regarding the effectiveness of LAIV4 are in agreement 
with results from the United Kingdom [24]. In contrast to our 
findings, a hospital-based Israeli study [11] found the children 
were protected after vaccination with IIV3, although this might 
be due to the different settings.
One strength of our register-based approach is the large size 
of the cohorts. We included essentially the whole population of 
Finnish children who were eligible for vaccination with LAIV4. 
Another strength is that we can distinguish between the brands 
of the vaccines recorded in the NVR. Consequently, the effec-
tiveness of LAIV4 and IIV3 can be compared within the same 
population during the same season addressing the regulatory 
request for brand-specific VE [25].
Figure 2. Vaccine effectiveness of LAIV4 and IIV3 against laboratory-confirmed influenza infection in 2-year-old children: influenza seasons 2015–2016 through 2017–2018, 
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In the present analysis, we revised our definition of chil-
dren aged 2 years during an influenza season that was used in 
a previously conducted study [2]. Extending the inclusion cri-
terion from children born in 2013 to children born November 
2012–December 2013 increased the cohort size in 2015–2016 
to over 60 000 despite the application of stricter exclusion cri-
teria following a refinement of the NVR’s quality assessment. 
Another difference from the previous analysis is the discrimi-
nation between fully and partially vaccinated children resulting 
in slightly higher VE estimates.
The general limitations associated with a register-based co-
hort study design have been described previously [4]. In partic-
ular, information bias and confounding may have affected the 
estimation of VE. Laboratory-confirmed influenza infection as 
recorded in the National Infectious Diseases Register does not 
describe the complete entity or spectrum of influenza disease in 
the Finnish population as many infections remain undetected, 
leading to outcome misclassification. Because the majority of 
patients tested for influenza are selected as part of routine clin-
ical procedure, the representativeness of the recorded cases is 
unknown and ascertainment bias cannot be excluded. If the in-
fection of an unvaccinated child is more likely to be confirmed 
than the infection of a vaccinated child, we expect to overesti-
mate VE, and vice versa. Bias due to outcome misclassification, 
however, seems negligible if misclassification equally affects un-
vaccinated and vaccinated cases. In addition, we assumed that 
data in the NVR are complete, allowing unbiased estimation of 
VE, although we cannot exclude that some vaccinations were 
given without being registered in the NVR—for example, when 
administered in the private sector despite the free offer of vacci-
nation in public health care centers.
Confounding due to demographic and health-related factors 
could have distorted our analyses. For instance, the higher IIV3 
uptake and lower incidence among children born in November 
or December might have contributed towards an overestima-
tion of IIV3 effectiveness in 2016–2017. Nevertheless, the cur-
rent analyses were not adjusted for confounding because the 
propensity score and covariate adjustments performed so far in 
2 similar studies [2, 26] did not reveal any major difference be-
tween crude and adjusted estimates. One possible explanation 
for such stability could be that 2-year-olds in Finland, a country 
with free public health care, form quite a homogenous group.
Great efforts are spent in motivating vaccine uptake prior to 
each influenza season. While the effectiveness by virus type is 
deemed the most important measure for vaccine manufacturers, 
for public health decision makers and individuals, such as parents 
of 2-year-old children at risk of influenza, the overall level of pro-
tection (effectiveness against any virus type) seems more relevant. 
The effectiveness of the nasal spray LAIV4 and the injectable IIV3 
varied across the influenza seasons and neither of the vaccines 
clearly excelled. Supported by the present analysis, the vaccina-
tion program in Finland now equally recommends LAIV4 and 
injectable, tetravalent inactivated influenza vaccines replacing 
IIV3. Moreover, with the recent extension of the program to cover 
influenza vaccinations of children aged 3 to 6 years, we expect to 
conduct even better-powered studies in the future.
Supplementary Data
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Consisting of data provided by the authors to benefit the reader, the posted 
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